Resumen
Objetivo: Evaluar los casos de osteonecrosis mandibular asociados al uso de fármacos antirresortivos tratados en la consulta externa de Cirugía Oral y Maxilofacial. Métodos: Estudio retrospectivo, transversal, con enfoque cuantitativo, de carácter descriptivo. Los datos fueron extraídos de consultas a registros médicos físicos, tabulados en hojas de cálculo de Microsoft Excel y analizados en el Paquete Estadístico para Ciencias Sociales. Resultados: La muestra estuvo constituida por 10 individuos, con predominio del sexo femenino (90%), con edad de 60 años o más. El alendronato fue el fármaco más utilizado (60%), la vía oral fue la más utilizada con 90% de los casos y el tiempo de exposición al medicamento fue de 4 a 5 años. La osteonecrosis en estadio 2 predominó en el 60% de los individuos, siendo la localización principal la mandíbula (80%), utilizándose tratamientos quirúrgicos y no quirúrgicos. Conclusión: La terapia prolongada asociada a enfermedades sistémicas aumenta el riesgo de desarrollar la enfermedad y se convierte en factores agravantes del tratamiento.
Referencias
AMIGUES C, et al. Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database. Joint Bone Spine, 2023; 90(6): 105599.
AREDE DP, et al. Osteonecrosis of the jaw with the use of bisphosphonates and treatment with laser therapy and magnetotherapy: a concise systematic review. MedNEXT Journal of Medical and Health Sciences, 2023; 4(2).
ASSILI Z, et al. A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva®) Related Osteonecrosis of the Jaw: A Retrospective Study. Journal of Clinical Medicine, 2021; 10(11): 2390.
BANSAL H. Osteonecrose da mandíbula relacionada a medicamentos: uma atualização. Revista Nacional de Cirurgia Maxilofacial, 2022; 13(1): 5.
BEDOGNI A, et al. Italian position paper (SIPMO‐SICMF) on medication‐related osteonecrosis of the jaw (MRONJ). Oral Diseases, 2024.
BRZAK BL, et al. Osteonecrose da mandíbula. Revista Odontologia, 2023; 11(1):23.
DIAS AA, et al. A Fotobiomodulação como alternativa no tratamento da osteonecrose dos maxilares relacionada à medicamentos: uma revisão da literatura. Revista Científica FACS, 2023; 23(2): 01-09.
DIAS KS, et al. Bisphosphonate-associated osteonecrosis of the jaw in oncology patient: case report. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology,2024; 137(6): e247.
EGUIA A, et al. Review and update on drugs related to the development of osteonecrosis of the jaw. Medicina oral, patologia oral y cirugia bucal, 2020; 25(1): e71.
GIUDICE A, et al. The case of medication-related osteonecrosis of the jaw addressed from a pathogenic point of view. Innovative therapeutic strategies: Focus on the most recent discoveries on oral mesenchymal stem cell-derived exosomes. Pharmaceuticals, 2020; 13(12): 423.
GUPTA M, GUPTA N. Bisphosphonate Related Jaw Osteonecrosis. StatPearls Publishing; 2024.
HANNA R, et al. A Systematic Review of Laser Photobiomodulation Dosimetry and Treatment Protocols in the Management of Medications-Related Osteonecrosis of the Jaws: A Rationalised Consensus for Future Randomised Controlled Clinical Trials. Pharmaceuticals, 2024; 17(8): 1011.
HOCHMULLER M. et al. Diagnóstico, tratamento e prevenção da osteonecrose maxilar relacionada a medicamentos. Revista Brasileira Multidisciplinar, 2021; 24(2):233-247.
IZZETTI R, et al. Panoramic Radiography Features of Medication‐Related Osteonecrosis of the Jaws (MRONJ). International Journal of Dentistry, 2023; 2023(1): 5358849.
KAWAHARA M, et al. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. International journal of implant dentistry,2021; 7(1): 47.
KO YY, et al. The Role of Cone Beam Computed Tomography (CBCT) in the Diagnosis and Clinical Management of Medication-Related Osteonecrosis of the Jaw (MRONJ). Diagnostics, 2024; 14(16): 1700.
KUROSHIMA S, et al. Medication‐related osteonecrosis of the jaw: a literature review and update. Genesis, 2022; 60(8-9): 23500.
KWOEN M, et al. Association between periodontal disease, tooth extraction, and medication‐related osteonecrosis of the jaw in women receiving bisphosphonates: A national cohort‐based study. Journal of Periodontology, 2023; 94(1): 98-107.
LIMONES A, et al. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis. Medicina oral, patologia oral y cirugia bucal, 2020; 25(3): e326.
LIU F, et al. Jaw osteoporosis: Challenges to oral health and emerging perspectives of treatment. Biomedicine & Pharmacotherapy, 2024; 177: 116995.
MAUCERI R, et al. Oral Squamous Cell Carcinoma Mimicking Medication-Related Osteonecrosis of the Jaws (MRONJ): A Case Series. Oral, 2021; 1(4): 326-331.
MELZER RS, et al. A retrospective study of medication-related osteonecrosis of the jaw in multiple myeloma patients. Journal of bone marrow transplantation and cellular therapy, 2023; 4(3): 209-209.
MEREY SE, et al. Pentoxifylline and Tocopherol in the Management of Stage III Medication-Related Osteonecrosis of the Jaw: A Case Report. Akdeniz Diş Hekimliği Dergisi, 2023; 2(3):162-167.
MIRELLI C, et al. Medication-related osteonecrosis of the jaw in dental practice: A retrospective analysis of data from the Milan cohort. Dentistry Journal, 2022; 10(5): 89.
MORAES CM, et al. Osteonecrose dos maxilares associada ao uso dos bisfosfonatos: revisão de literatura. Revista saúde multidisciplinar, 2020; 8(2).
MORAIS RPL, et al. IS The use of pentoxifylline and tocopherol effective in the treatment of osteoradionecrosis of the jaws or for the treatment of medication-osteonecrosis of the jaw? an overview. Journal of Stomatology, Oral and Maxillofacial Surgery, 2024;101959.
OIZUMI T, et al. Osteonecrosis of the jaw in a patient treated with alendronate and then denosumab: A case of dramatic amelioration by minocycline and then etidronate. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 2025; 37(2): 348-355.
RIVAS ANM, DONAIRE, JAR. Tratamiento conservador de osteonecrosis maxilar asociada a medicamentos refractaria mediante el uso de protocolo PENTO: reporte de un caso. Odontoestomatología, 2021: 23(38).
RUAN H. et al. Medication-related osteonecrosis of the jaw: a retrospective single center study of recurrence-related factors after surgical treatment. Clinical Oral Investigations, 2024; 28(10): 1-12.
RUGGIERO SL, et al. American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaws—2022 update. Journal of oral and maxillofacial surgery, 2022 80 (5): 920-943.
ŞAHIN O, et al. Combined approach to treatment of advanced stages of medication-related osteonecrosis of the jaw patients. Brazilian Journal of Otorhinolaryngology, 2022; 88(4): 613-620.
SAKAMOTO Y, et al. Medication-related osteonecrosis of the jaw without osteolysis on computed tomography: a retrospective and observational study. Scientific Reports, 2023; 13(1):12890.
SANTOS WB, et al. Osteonecrose dos Maxilares associada ao uso crônico de bisfosfonatos: relato de caso. Revista Eletrônica Acervo Saúde, 2020; 12(2): e2398.
SEO DD, BORKE, JL. Medication-Related Osteonecrosis of the Jaw–2024 Update. Oral Health Dental Sci, 2024; 8(1):1-6.
SHIN JW, et al. Radiological manifestations and clinical findings of patients with oncologic and osteoporotic medication-related osteonecrosis of the jaw. Scientific reports, 2024; 14(1): 8744.
SRIVASTAVA A, et al. Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis. Journal of Immunotherapy and Precision Oncology, 2021; 4(4): 196-207.
STRAUB A, et al. Bone concentration of ampicillin/sulbactam: a pilot study in patients with osteonecrosis of the jaw. International Journal of Environmental Research and Public Health, 2022; 19 (22): 14917.
VELASKI DP, et al. Etiopatogenia da osteonecrose maxilar relacionada a bisfosfonatos. Biosaúde, 2020; 22(2): 84-96.
WAN JT, et al. Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors. Bone research; 2020; 8(1):14.
YAROM N, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. Journal of Clinical Oncology, 2019; 37(25): 2270-2290.
